Alphaject Technology


1. Whalen GF, Sullivan M, Piperdi B, Wasseff W and Galili U. Cancer Immunotherapy by intratumoral injection of α-gal glycolipids.  (2012). Anticancer Res. 32(9):3861-8.

2. Galili U, Albertini A, Sondel P, Wigglesworth K, Sullivan M and Whalen G.  (2010). In Situ Conversion of Melanoma Lesions into Autologous Vaccine by Intratumoral Injections of α-gal Glycolipids. Cancers (Basel) 2(2):773-793.

3. Abdel-Motal UM, Wigglesworth K and Galili U. (2009). Intratumoral injection of α-gal glycolipids induces a protective anti-tumor T cell response which overcomes Treg activity. Cancer Immunol Immunother 58: 1545-155.

4. Galili U, Wigglesworth K and Abdel-Motal UM. (2007). Intratumoral injection of α-gal glycolipids induces xenograft-like destruction and conversion of lesions into endogenous vaccines. J Immunol 178: 4676-4687.

5. Galili U, Macher BA, Buehler JS and Shohet SB. (1985). Human natural anti-α-galactosyl IgG. II. The specific recognition of α (1,3)- linked galactose residues. J Exp Med 16: 573-582.

6. Galili U, Rachmilewitz EA, Peleg A and Flechner I. (1984). A unique natural human IgG antibody with anti-α-galactosyl specificity. J Exp Med 160: 1519-1531.